medigraphic.com
Revista Médica Sinergia

2020, Number 04

Next >>

Revista Médica Sinergia 2020; 5 (04)

Management of hiv patients with high cardiovascular risk

Téllez VIJ, Clinton NCF, Elizondo VJR

Language: Spanish
References: 19
Page: 1-10
PDF size: 134.14 Kb.


ABSTRACT

The increase in the global prevalence of Human Immunodeficiency Virus, likewise the increase in cardiovascular manifestations associated with this disease are relevant issues in current medicine. The Human Immunodeficiency Virus changes in its epidemiology, transforming from an acute disease to a chronic disease. Thanks in part to the new generation of antiretrovirals, which produce fewer side effects, and also show an improvement in adherence to treatment that results in a life expectancy close to the general population. The control and treatment of cardiovascular risk factors are fundamental in therapeutic treatment. Patients with optimal treatment do not have a worse prognosis than the population without infection, but have an increase in the rate of recurrence of cardiovascular complications.


REFERENCES

  1. Feinstein M, Nance R, Delaney J, Heckbert S, Budoff M, Drozd D et al. Mortality following myocardial infarction among HIV-infected persons: the Center for AIDS Research Network Of Integrated Clinical Systems (CNICS).BMC Medicine [Internet].2019[citado 26/1/2020]; 17(1). https://doi.org/10.1186/s12916- 019-1385-7

  2. Butler J, Kalogeropoulos AP, Anstrom KJ, Hsue PY, Kim RJ, Scherzer R, et al. Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. Journal of Cardiac Failure [Internet]. 2018 [citado: 27/12/2019]; 24(4):255-265. https://doi.org/10.1016/j.cardfail.2018.02.001

  3. Kaplan RC, Hanna DB, Kizer JR. Recent Insights Into Cardiovascular Disease (CVD) Risk Among HIVInfected Adults. Current HIV/AIDS Reports [Internet]. 2016 [citado: 27/12/2019; 13(1):44- 52. https://doi.org/10.1007/s11904-016-0301-4

  4. Lambert CT, Sandesara PB, Hirsh B, Shaw LJ, Lewis W, Quyyumi AA, et al. HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review. HIV Medicine [Internet]. 2016 [citado: 27/12/2019]; 17(6):411-424. https://doi.org/10.1111/hiv.12346

  5. Wandeler G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive adults on anti-retroviral therapy across the globe: comparisons with general population. Current Opinion in HIV and AIDS [Internet]. 2016 [citado: 27/12/2019]; 11(5):492-500. https://doi.org/10.1097/COH.0000000000000298

  6. Boccara F, Cohen A. VIH y cardiopatía:¿qué deben saber los cardiólogos? Revista Española de Cardiología[Internet]. 2016 [citado: 27/12/2019]; 69(12):1126- 1130. https://doi.org/10.1016/j.recesp.2016.05.037

  7. Vicente Muller E, Agostinho Gimeno S. Risk factors for cardiovascular disease in HIV/AIDS patients treated with highly active antiretroviral therapy (HAART) in the central-southern region of the state of Paraná - Brazil. Ciência & Saúde Coletiva [Internet]. 2019 [citado: 27/12/2019]; 24(5):1903- 1914. https://doi.org/10.1590/1413-81232018245.16682017

  8. Hawkins K, Brown T, Margolick J, Erlandson K. Geriatric syndromes. AIDS. [Internet] 2017[citado 26/1/2020]; 31:S137-S146. https://doi.org/10.1097/QAD.0000000000001444

  9. Saiz LC, Gorricho J, Garjón J, Celaya MC, Muruzábal L, Malón MDM, et al. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease (Review). Cochrane Data-base of Systematic Reviews [Internet]. 2017 [citado: 27/12/2019]; 10: CD010315. https://doi.org/10.1002/14651858.CD010315.pub3

  10. Chastain DB, Stover KR, Riche DM. Evidence-based review of statin use in patients with HIV on antiretroviral therapy. Journal of Clinical & Translational Endocrinology [Internet]. 2017 [citado: 27/12/2019]; 8:6-14. https://doi.org/10.1016/j.jcte.2017.01.004

  11. Ahmed M, Woodward C, Mital D. Metabolic clinic for individuals with HIV/AIDS. Cardiovascular Endocrinology [Internet].2017[citado: 27/1/2020]; 6(3):109- 112. https://doi.org/10.1097/XCE.0000000000000128

  12. Freiberg MS, Chang CCH, Skanderson M, Patterson OV, DuVall SL, Brandt CA, et al. Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era. JAMA Cardiology [Internet].2017 [citado:27/12/2019]; 2(5):536-546.https://doi.org/10.1001/jamacardio.2017.0264

  13. Hsue PY, Waters DD. Heart failure in persons living with HIV infection. Current Opinion in HIV and AIDS [Internet].2017 [citado: 27/12/2019];12(6):534-539. https://doi.org/10.1097/COH.0000000000000409

  14. Alikhani A, Morin H, Matte S, Alikhani P, Tremblay C, Durand M. Association between li-podystrophy and length of exposure to ARTs in adult HIV-1 infected patients in Montreal. BMC Infectious Diseases [Internet]. 2019 [citado: 27/12/2019];19(1). https://doi.org/10.1186/s12879-019-4446-9

  15. Raposeiras-Roubín S, Triant V. Cardiopatía isquémica en el VIH: profundizando en el conocimiento del riesgo cardiovascular. Rev Esp Cardiol [Internet]. 2016 [citado: 27/12/2019]; 69(12):1204- 1213. https://doi.org/10.1016/j.recesp.2016.08.035

  16. Valderrama Beltrán SL Gualtero SM, Quiroga C, Garzón JR, Lowenstein de Mendivelson E, Tamara JR, et al. Evaluación y manejo del riesgo cardiovascular en infección por VIH. Consenso de expertos ACIN. Infectio [Internet]. 2018 [citado: 27/12/2019]; 23(S1):73-91. https://doi.org/10.22354/in.v23i1.762

  17. De Wit S, Battegay M, D'Arminio Monforte A, Lundgren J, Oprea C, Antinori A, et al. European AIDS Clinical Society Second Standard of Care Meeting, Brussels 16-17 November 2016: a summary. HIV Medicine [Internet].2017 [citado: 27/12/2019]; 19(2):77-80. https://doi.org/10.1111/hiv.12559

  18. Documento de consenso de GeSIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos con infección por el virus de la inmunodeficiencia humana (Actualización enero 2015). Enfermedades Infecciosas y Microbiología Clínica [Internet]. 2015 [citado: 27/12/2019];33(8):543.e1- 543.e43. https://doi.org/10.1016/j.eimc.2015.03.016

  19. Regan S, Meigs J, Grinspoon S, Triant V. Determinants of Smoking and Quitting in HIV-Infected Individuals. PLOS ONE [Internet].2016 [citado 26/1/2020];11(4):e0153103. https://doi.org/10.1371/journal.pone.0153103




2020     |     www.medigraphic.com